Metabolic reprogramming represents a targetable mechanism to overcome acquired resistance to venetoclax in acute myeloid leukemia (2025)
- Authors:
- USP affiliated authors: REGO, EDUARDO MAGALHÃES - FM ; CÂMARA, NIELS OLSEN SARAIVA - ICB ; LOTUFO, LETICIA VERAS COSTA - ICB ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; QUEIROZ, GUSTAVO NERY DE - ICB ; LIMA, KELI CRISTINA DE - FM ; CIPELLI, MARCELLA - ICB
- Unidades: FM; ICB
- DOI: 10.1016/j.bbadis.2025.168065
- Subjects: FARMACOLOGIA; IMUNOLOGIA; LEUCEMIA MIELOIDE AGUDA; ANTINEOPLÁSICOS; PROTO-ONCOGENES; FOSFOPROTEÍNAS; TRANSDUÇÃO DE SINAL CELULAR; SULFONAMIDAS; FOSFATOS DE AÇÚCAR
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- ISSN: 1879-260X
- Volume/Número/Paginação/Ano: v. 1872, art. 168065, 12 p., 2026
- Este artigo NÃO possui versão em acesso aberto
-
Status: Nenhuma versão em acesso aberto identificada -
ABNT
QUEIROZ, Gustavo Nery de et al. Metabolic reprogramming represents a targetable mechanism to overcome acquired resistance to venetoclax in acute myeloid leukemia. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, v. 1872, p. 12 , 2025Tradução . . Disponível em: https://doi.org/10.1016/j.bbadis.2025.168065. Acesso em: 10 mar. 2026. -
APA
Queiroz, G. N. de, Lima, K., Cipelli, M., Tomaz, V., Cortez, L. G. F., Silva, M. de F. B., et al. (2025). Metabolic reprogramming represents a targetable mechanism to overcome acquired resistance to venetoclax in acute myeloid leukemia. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1872, 12 . doi:10.1016/j.bbadis.2025.168065 -
NLM
Queiroz GN de, Lima K, Cipelli M, Tomaz V, Cortez LGF, Silva M de FB, Guedes RLM, Campregher PV, Rego EM, Câmara NOS, Costa-Lotufo LV, Machado Neto JA. Metabolic reprogramming represents a targetable mechanism to overcome acquired resistance to venetoclax in acute myeloid leukemia [Internet]. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2025 ; 1872 12 .[citado 2026 mar. 10 ] Available from: https://doi.org/10.1016/j.bbadis.2025.168065 -
Vancouver
Queiroz GN de, Lima K, Cipelli M, Tomaz V, Cortez LGF, Silva M de FB, Guedes RLM, Campregher PV, Rego EM, Câmara NOS, Costa-Lotufo LV, Machado Neto JA. Metabolic reprogramming represents a targetable mechanism to overcome acquired resistance to venetoclax in acute myeloid leukemia [Internet]. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2025 ; 1872 12 .[citado 2026 mar. 10 ] Available from: https://doi.org/10.1016/j.bbadis.2025.168065 - Metabolic reprogramming drives acquired venetoclax resistance in Acute Myeloid Leukemia and reveals targetable vulnerabilities
- Overcoming acquired venetoclax resistance in acute myeloid leukemia through cell metabolism targeting
- NT157 exhibits antineoplastic effects by targeting IRS and STAT3/5 signaling in multiple myeloma
- Gut microbiota resilience mechanisms against pthogen infection and its role in infammatory Bowel Disease
- Synthesis and evaluation of 2-substituted quinazolin-4(3H)-ones as potential antileukemic agents
- In Silico, in vitro, and in vivo studies of a 2-substituted quinazolin-4(3H)-one in T-cell acute lymphoblastic leukemia
- Cellular and molecular effects of Eribulin in preclinical models of hematologic neoplasms
- Chromomycin A2 exhibits antileukemic effects by coordinated disruption of survival pathways
- All-trans retinoic acid potentiates cell death induced by quizartinib in acute myeloid leukemia with FLT3-ITD mutations
- Translational investigation of tolinapant (ASTX660) in acute myeloid leukemia by integrating clinical, bioinformatic and pharmacological approaches
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
